The effect of diabetes mellitus on pharmacokinetics, pharmacodynamics and adverse drug reactions of anticancer drugs
| Autor: | Homa Nomani, Habibeh Mashayekhi-Sardoo, Amirhossein Sahebkar, Amir Hooshang Mohammadpour |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Drug-Related Side Effects and Adverse Reactions Paclitaxel Physiology medicine.medical_treatment Clinical Biochemistry Antineoplastic Agents Type 2 diabetes 03 medical and health sciences 0302 clinical medicine Pharmacokinetics Neoplasms Internal medicine medicine Animals Humans Insulin Chemotherapy business.industry Cancer Cell Biology medicine.disease Clinical trial 030104 developmental biology Diabetes Mellitus Type 2 Doxorubicin Hyperglycemia 030220 oncology & carcinogenesis Pharmacodynamics Liver cancer business Adverse drug reaction |
| Zdroj: | Journal of Cellular Physiology. 234:19339-19351 |
| ISSN: | 1097-4652 0021-9541 |
| Popis: | Diabetes mellitus (DM) and cancer are global problems carrying huge human, social, and economic impact. Type 2 diabetes (T2DM) is associated with an increased risk for a number of cancers, including breast, pancreatic, and liver cancer. Moreover, adverse drug reactions are higher in paitents with cancer with T2DM compared to cancer patients without T2DM. Cellular mechanisms of hyperglycemia and chemotherapy efficacy may be different depending upon the particular cancer type and the condition of the patient. This review evaluates the effect of DM on the pharmacokinetic, pharmacodynamic, and adverse drug reactions of commonly used anticancer drugs such as cisplatin, methotrexate, paclitaxel, doxorubicin, and adriamycin in both clinical and animal models. A literature search was conducted in scientific databases including Web of Science, PubMed, Scopus, and Google Scholar including the relevant keywords. The results of the effectiveness of anticancer therapies in patients with DM are, however, inconsistent because DM can negatively impact multiple diverse entities including nerves and vascular structures, insulin-like growth factor 1, the function of the innate immune system, drug pharmacokinetics, the expression levels of hepatic CYP450 , Mdr 1b and enzymes that then lead to drug toxicity. However, in a few circumstances, DM led to attenuation of the toxicity of anticancer drugs secondary to attenuation of the energy-dependent renal uptake process. Overall, the impact of DM on patients with cancer is variable because of the diverse types of cancers and the spectrum of anticancer drugs. With respect to the evidence for cancer involvement in DM pathophysiology and the response to anticancer treatment in patients with DM, many questions still remain and further clinical trials are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text